United States: Anthropic stated that its Claude artificial intelligence model helped discover a novel enzyme system with properties resembling mechanisms involved in CRISPR gene-editing technology, marking the first reported result from the AI company’s biology research efforts.
The finding comes days after Reuters reported that Anthropic had quietly established a wet lab in the San Francisco Bay Area as the company expands its work in life sciences and drug-related research beyond purely computer-based AI development.
Anthropic stated that Claude analysed large DNA databases and identified an unusual biological system built around a reverse transcriptase (RT), an enzyme that copies RNA into DNA. The company has named the newly identified system array-associated reverse transcriptases, or ART.
According to Anthropic, ART contains repeating DNA sequences that resemble patterns observed in CRISPR systems. The company stated that these features could provide researchers with new information about how certain biological systems function.
Anthropic noted that the underlying reverse transcriptase had already been identified in previous scientific studies. However, Claude appeared to be the first to recognise important features connecting the enzyme to a broader system. Those features included an array of non-coding DNA sequences and an additional protein whose function remains unknown, according to the company.

The discovery highlights how AI models can be used to analyse large biological datasets and identify patterns that may be difficult to detect through conventional approaches. Anthropic is increasingly exploring applications of its AI systems in scientific research as competition grows among technology companies to apply AI to biology and drug discovery.
The company’s expansion into biological research also represents a move beyond the development of general-purpose AI models. Its newly established wet lab is intended to support research that requires physical laboratory work alongside computational analysis.
The ART finding does not mean the system is a new form of CRISPR. Instead, Anthropic stated that certain features of the system resemble mechanisms observed in gene-editing technology. Further research will be needed to determine the biological role of the newly identified components and establish whether the system could have practical applications.
The announcement comes as AI companies increasingly position their models as research tools capable of assisting scientists with tasks including analysing biological data, identifying molecular patterns and generating potential research hypotheses.
Anthropic’s latest finding could provide an early indication of how Claude is being applied within the company’s growing biology research programme.

